<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477320</url>
  </required_header>
  <id_info>
    <org_study_id>11.0170</org_study_id>
    <nct_id>NCT01477320</nct_id>
  </id_info>
  <brief_title>Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.</brief_title>
  <official_title>Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients. Prospective, Double-blind, Randomized, Placebo-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mohamed Saad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      study is to determine if proton pump inhibitors plus enteral nutrition is superior to enteral
      nutrition alone as a stress ulcer prophylaxis strategy in critically ill patients in terms of
      incidence of overt and significant GI bleeding related to stress gastropathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With GI Bleeding</measure>
    <time_frame>Subjects will be followed from date of randomization until discharge from the ICU or cessation of Enteral Nutrition (EN) and successful initiation of oral feeds up to 100 weeks.</time_frame>
    <description>Incidence of overt GI bleeding (as defined by the presence of coffee ground emesis, hematemesis of bright red blood, melena, or hematochezia) seen with Proton Pump Inhibitor (PPI) and EN versus EN alone in critically ill patients.
Incidence of significant GI bleeding, defined by a 3-point decrease in hematocrit within 24 hours accompanied by signs of overt GI bleeding, or by an unexplained 6-point decrease in hematocrit during any 48 hour period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With ICU-acquired C. Difficile Pseudomembranous Colitis.</measure>
    <time_frame>Subjects will be followed until discharge from the ICU or cessation of EN and successful initiation of oral feeds up to 100 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Gastrointestinal Hemorrhage</condition>
  <condition>Clostridium Difficile Colitis</condition>
  <arm_group>
    <arm_group_label>Pantoprazole 40mg IV daily and tube feed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and tube feed.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole 40 mg IV daily and tube feed.</intervention_name>
    <description>Patients randomized to the control group &quot;active Comparator&quot; will receive tube feed plus an Pantoprazole 40 mg IV daily.</description>
    <arm_group_label>Pantoprazole 40mg IV daily and tube feed</arm_group_label>
    <other_name>Tube feed formula:(Vital AF &quot;Advanced Formula&quot; 1.2 Cal(TM),Abbott,Columbus,OH)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo and tube feed</intervention_name>
    <description>Patients randomized to Placebo group &quot;placebo Comparator&quot; will receive tube feed plus an Placebo.</description>
    <arm_group_label>Placebo and tube feed.</arm_group_label>
    <other_name>Tube feed formula:(Vital AF &quot;Advanced Formula&quot; 1.2 Cal(TM),Abbott,Columbus,OH)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Admission to the medical ICU at University of Louisville Hospital or Jewish Hospital

          -  Expected need for mechanical ventilation &gt; 48 hours

          -  No contraindication to EN within the first 24 hours after admission to the ICU

        Exclusion Criteria:

          -  Evidence of active GI bleeding during current hospitalization prior to study entry

          -  Admission to ICU with primary diagnosis of burn injury

          -  Closed head injury or increased intracranial pressure

          -  Partial or complete gastrectomy

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Saad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Louisville hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <results_first_submitted>August 17, 2017</results_first_submitted>
  <results_first_submitted_qc>December 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 16, 2018</results_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Mohamed Saad</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>Enteral Nutrition</keyword>
  <keyword>Stress Ulcer Prophylaxis</keyword>
  <keyword>Critically Ill Patients</keyword>
  <keyword>Overt and significant GI bleeding</keyword>
  <keyword>Stress gastropathy</keyword>
  <keyword>Clostridium Difficile pseudomembranous colitis</keyword>
  <keyword>Vital AF</keyword>
  <keyword>Small peptide fish oil structured lipids</keyword>
  <keyword>Fructose oligosaccharide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started in July 2013 in the medical ICU of University of Louisville Hospital. In July 2014, a second recruitment site (medical ICU at Jewish Hospital) was added as a second site for recruitment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pantoprazole 40mg IV Daily and Tube Feed</title>
          <description>Pantoprazole 40 mg IV daily and tube feed.: Patients randomized to the control group &quot;active Comparator&quot; will receive tube feed plus an Pantoprazole 40 mg IV daily.</description>
        </group>
        <group group_id="P2">
          <title>Placebo and Tube Feed.</title>
          <description>Placebo and tube feed: Patients randomized to Placebo group &quot;placebo Comparator&quot; will receive tube feed plus an Placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pantoprazole 40mg IV Daily and Tube Feed</title>
          <description>Pantoprazole 40 mg IV daily and tube feed.: Patients randomized to the control group &quot;active Comparator&quot; will receive tube feed plus an Pantoprazole 40 mg IV daily.</description>
        </group>
        <group group_id="B2">
          <title>Placebo and Tube Feed.</title>
          <description>Placebo and tube feed: Patients randomized to Placebo group &quot;placebo Comparator&quot; will receive tube feed plus an Placebo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>The patient excluded from analysis were extubated too soon after enrollment before starting tube feed</population>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="49.5" upper_limit="68"/>
                    <measurement group_id="B2" value="58" lower_limit="40.5" upper_limit="66.5"/>
                    <measurement group_id="B3" value="60" lower_limit="40.5" upper_limit="68.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With GI Bleeding</title>
        <description>Incidence of overt GI bleeding (as defined by the presence of coffee ground emesis, hematemesis of bright red blood, melena, or hematochezia) seen with Proton Pump Inhibitor (PPI) and EN versus EN alone in critically ill patients.
Incidence of significant GI bleeding, defined by a 3-point decrease in hematocrit within 24 hours accompanied by signs of overt GI bleeding, or by an unexplained 6-point decrease in hematocrit during any 48 hour period.</description>
        <time_frame>Subjects will be followed from date of randomization until discharge from the ICU or cessation of Enteral Nutrition (EN) and successful initiation of oral feeds up to 100 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pantoprazole 40mg IV Daily and Tube Feed</title>
            <description>Pantoprazole 40 mg IV daily and tube feed.: Patients randomized to the control group &quot;active Comparator&quot; will receive tube feed plus an Pantoprazole 40 mg IV daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Tube Feed.</title>
            <description>Placebo and tube feed: Patients randomized to Placebo group &quot;placebo Comparator&quot; will receive tube feed plus an Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With GI Bleeding</title>
          <description>Incidence of overt GI bleeding (as defined by the presence of coffee ground emesis, hematemesis of bright red blood, melena, or hematochezia) seen with Proton Pump Inhibitor (PPI) and EN versus EN alone in critically ill patients.
Incidence of significant GI bleeding, defined by a 3-point decrease in hematocrit within 24 hours accompanied by signs of overt GI bleeding, or by an unexplained 6-point decrease in hematocrit during any 48 hour period.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With ICU-acquired C. Difficile Pseudomembranous Colitis.</title>
        <time_frame>Subjects will be followed until discharge from the ICU or cessation of EN and successful initiation of oral feeds up to 100 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pantoprazole 40mg IV Daily and Tube Feed</title>
            <description>Pantoprazole 40 mg IV daily and tube feed.: Patients randomized to the control group &quot;active Comparator&quot; will receive tube feed plus an Pantoprazole 40 mg IV daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Tube Feed.</title>
            <description>Placebo and tube feed: Patients randomized to Placebo group &quot;placebo Comparator&quot; will receive tube feed plus an Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With ICU-acquired C. Difficile Pseudomembranous Colitis.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pantoprazole 40mg IV Daily and Tube Feed</title>
          <description>Pantoprazole 40 mg IV daily and tube feed.: Patients randomized to the control group &quot;active Comparator&quot; will receive tube feed plus an Pantoprazole 40 mg IV daily.</description>
        </group>
        <group group_id="E2">
          <title>Placebo and Tube Feed.</title>
          <description>Placebo and tube feed: Patients randomized to Placebo group &quot;placebo Comparator&quot; will receive tube feed plus an Placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mohamed Saad</name_or_title>
      <organization>University of Louisville</organization>
      <phone>5028525841</phone>
      <email>mohamed.saad@louisville.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

